[Skip to Content]
[Skip to Content Landing]
Article
June 1951

EFFECTS OF VERILOID® ON ESSENTIAL HYPERTENSIONA New Derivative of Veratrum Viride

Author Affiliations

ST. LOUIS; GARY, IND.

From the Hypertension Division, Department of Internal Medicine, the Department of Physiology and the Division of Gerontology, Washington University School of Medicine, and the Homer G. Phillips, St. Louis City and Barnes Hospitals, under a Grant-in-Aid from Eli Lilly & Company, Indianapolis 6, and the National Heart Institute.

AMA Arch Intern Med. 1951;87(6):789-794. doi:10.1001/archinte.1951.03810060016002
Abstract

INTEREST in the use of preparations of Veratrum viride for treatment of essential hypertensive vascular disease has recently been revived. This interest stems from a number of reports indicating favorable effects on blood pressure and a better understanding of the pharmacologic action of the Veratrum alkaloids.1 The preparations employed clinically have been, for the most part, mixtures of alkaloids said to be therapeutically effective and efficiently nontoxic for extended use. More recently,2 oral administration of a purified alkaloidal fraction of Veratrum viride, standardized on a chemical basis and given the proprietary name veriloid,®1b has been reported to produce lowering of blood pressure for periods as long as five months, while accompanied with "fewer toxic reactions than any other oral preparation of Veratrum viride presently available."2 Its pharmacologic actions have been described.3 Because of the promising clinical results reported, we studied the effects on arterial pressure

First Page Preview View Large
First page PDF preview
First page PDF preview
×